epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Eligard
    leuprolide
  • remove Kionex
    sodium polystyrene sulfonate
  • remove Maxalt-MLT
    rizatriptan
  • remove Zyprexa Relprevv
    olanzapine

multicheck MultiCheck Results - 2 Interactions

Smiley face Smiley face

Monitor/Modify Tx

Smiley face Smiley face Maxalt-MLT (rizatriptan) + Zyprexa Relprevv (olanzapine)

Monitor/Modify Tx


rizatriptan + olanzapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis (additive effects)

Caution Advised

Smiley face Smiley face Eligard (leuprolide) + Zyprexa Relprevv (olanzapine)

Caution Advised


leuprolide + olanzapine

caution advised: combo may decr. leuprolide efficacy (olanzapine may cause hyperprolactinemia, decr. GnRH receptors)

Additional Considerations

Smiley face Smiley face sodium polystyrene sulfonate in Kionex

separate administration from other oral drugs at least 3h before or after sodium polystyrene sulfonate; if gastroparesis, separate administration from other oral drugs by 6h; sodium polystyrene sulfonate may decr. absorption of concomitant oral drugs

some formulations of sodium polystyrene sulfonate contain sorbitol

Smiley face Smiley face rizatriptan in Maxalt-MLT

add MAO inhibitor to Interaction Check if recent (14 days) use

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback Cookie Preferences
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information